Description

A patient with malignant lymphoma can be clinically staged based on the extent of the disease. A staging system based on the Ann Arbor system was presented at the 12th International Conference (2013) for Malignant Lymphoma in Lugano, Switzerland.


Patient selection: malignant lymphoma, Hodgkin's or non-Hodgkin's disease

 

Parameters:

(1) number of nodes involved

(2) extranodal involvement

(3) location of the affected nodes

 

Nodal tissue includes the tonsils, Waldeyer's ring and the spleen.

 

Categories:

(1) limited: Stage I or II

(2) bulky disease (limited or advanced depending on histology and prognostic features)

(3) advanced: Stage III or IV

 

Stage I - one of the following:

(1) one lymph node

(2) one group of adjacent nodes

(3) single extranodal lesion without lymph node involvement

 

Stage II - one of the following:

(1) two or more nodal groups on the same side of the diaphragm

(2) Stage I or II nodal disease AND limited contiguous extranodal involvement

 

Stage II bulky:

(1) for Hodgkin's disease: (single nodal mass >= 10 cm in diameter) OR (more than one third of transthoracic diameter)

(2) for follicular lymphoma: single nodal mass >= 6 cm

(3) for DLBCL: single nodal mass >= 6 cm to >= 10 cm

 

Stage III - one of the following:

(1) nodes involved on both sides of the diaphragm

(2) nodes involved above the diaphragm AND spleen involved

 

Stage IV:

(1) any Stage with noncontiguous extranodal involvement


To read more or access our algorithms and calculators, please log in or register.